Biosenic SA (BIOS) | Stock Overview & Key Data
Biosenic SA | Small-cap | Healthcare
Biosenic SA | Small-cap | Healthcare
Biosenic SA Performance Comparison
Stock Range
Today's Range
Low: €0.00
High: €0.00
on September 23, 2025
52 Week Range
Low: €0.00
High: €0.02
on September 23, 2025
on December 16, 2024
All-Time High: €28.90 on February 9, 2015
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Market Cap
€1.6M
EPS
-0.04
P/E Ratio (TTM)
0.00
Forward P/E
-0.05
P/B Ratio
N/A
PEG Ratio
-0.05
Div. Yield
N/A
ROE
126.75%
Beta
-2.429
Debt to Equity
-1.31
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-17.33%
Profit Margin
-279.17%
Returns and Earnings
Return on Assets (TTM)
-22.77%
Return on Equity (TTM)
126.75%
EBITDA
€-3.6M
Net Income (TTM)
€-7.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.02
Quarterly Revenue Growth (YoY)
638.10%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Biosenic SA BIOS | 1.57M Small-cap | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -80.00% | -98.25% | -99.73% |
| Argenx SE ARGX | 38.42B Large-cap | -1.07% | 11.60% | 35.45% | 11.72% | 3.34% | 31.86% | 71.29% | 177.33% |
| UCB S.A UCB | 39.10B Large-cap | 0.49% | 4.66% | 25.61% | 15.07% | 7.92% | 27.98% | 190.35% | 111.49% |
| European Medical ALEMS | 21.80M Small-cap | 22.62% | 9.57% | 9.57% | -16.94% | -14.17% | -24.60% | -87.28% | -92.81% |
| Celyad Oncology S.A CYAD | 13.43M Small-cap | 3.33% | -22.50% | -22.50% | -46.55% | -53.73% | 14.81% | -79.19% | -96.23% |
| Onward Medical N.V ONWD | 245.24M Mid-cap | 1.54% | 4.35% | 20.55% | 10.92% | -1.12% | 3.13% | -0.38% | -58.56% |
Ownership & Short Interest
Insider Ownership
14.14%
Institutional Ownership
1.87%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
2M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BIOS's 52-week high and low?
- In the last 52 weeks, Biosenic SA reached a high of €0.02 (on December 16, 2024) and a low of €0.00 (on September 23, 2025).
- What is the market cap and P/E ratio for BIOS?
- Curious about Biosenic SA's size and valuation? Its market capitalization stands at 1.57M. When it comes to valuation, the P/E ratio (trailing twelve months) is 0.00, and the forward P/E (looking ahead) is -0.05.
- Does BIOS pay dividends? If so, what's the yield?
- As for dividends, Biosenic SA isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Biosenic SA's main competitors or similar companies to consider before investing?
When looking at Biosenic SA, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Argenx SE
ARGX38.42B Healthcare Biotechnology 31.86% 71.29% UCB S.A
UCB39.10B Healthcare Biotechnology 27.98% 190.35% European Medical
ALEMS21.80M Healthcare Biotechnology -24.60% -87.28% Celyad Oncology S.A
CYAD13.43M Healthcare Biotechnology 14.81% -79.19% Onward Medical N.V
ONWD245.24M Healthcare Biotechnology 3.13% -0.38% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Biosenic SA? (e.g., ROE, Debt/Equity)
- To get a sense of Biosenic SA's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 126.75%, the Debt to Equity ratio from the most recent quarter is -1.31, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for BIOS?
- Looking at Biosenic SA's growth, its revenue over the trailing twelve months (TTM) was €3M. Compared to the same quarter last year (YoY), quarterly revenue grew by 638.10%, and quarterly earnings saw a YoY growth of N/A.
- How much of BIOS stock is held by insiders and institutions?
- Wondering who owns Biosenic SA stock? Company insiders (like executives and directors) hold about 14.14% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 1.87%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.